Papers in Press. First published July 9, 2004 as doi: /clinchem Nonstandard abbreviations: PHA, primary hyperaldosteronism; PAC,
|
|
- Andra Cunningham
- 6 years ago
- Views:
Transcription
1 Papers in Press. First published July 9, 2004 as doi: /clinchem Clinical Chemistry 50: (2004) Endocrinology and Metabolism Rapid Screening Test for Primary Hyperaldosteronism: Ratio of Plasma Aldosterone to Renin Concentration Determined by Fully Automated Chemiluminescence Immunoassays Frank Holger Perschel, 1* Rudolf Schemer, 3 Lysann Seiler, 4 Martin Reincke, 4 Jaap Deinum, 5 Christiane Maser-Gluth, 6 David Mechelhoff, 1 Rudolf Tauber, 1 and Sven Diederich 2 Background: The ratio of plasma aldosterone concentration to plasma renin activity (PAC/PRA) is the most common screening test for primary hyperaldosteronism (PHA), but it is not standardized among laboratories. We evaluated new automated assays for the simultaneous measurement of PAC and plasma renin concentration (PRC). Methods: We studied 76 healthy normotensive volunteers and 28 patients with confirmed PHA. PAC and PRC were measured immunochemically in EDTA plasma on the Nichols Advantage chemiluminescence analyzer, and PRA was determined by an activity assay. Results: In volunteers, PAC varied from 33.3 to 1930 pmol/l, PRA from 1.13 to 19.7 ng ml 1 h 1, and PRC from 5.70 to 116 mu/l. PAC/PRA ratios ranged from 4.35 to 494 (pmol/l)/(ng ml 1 h 1 ) and PAC/PRC ratios from 0.69 to 71.0 pmol/mu. In PHA patients, PAC ranged from 158 to 5012 pmol/l, PRA from 0.40 to 1.70 ng ml 1 h 1, and PRC from 0.80 to 11.7 mu/l. PAC/ PRA ratios were between 298 and 6756 (pmol/l)/ 1 Clinical Chemistry and Pathobiochemistry and 2 Endocrinology, Diabetes, and Nutritional Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. 3 Nichols Institute Diagnostics, Bad Vilbel, Germany. 4 Department of Internal Medicine II, University of Freiburg, Freiburg, Germany. 5 Department of Medicine, University Medical Center Nijmegen, The Netherlands. 6 Department of Pharmacology, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany. *Address correspondence to this author at: Institut für Klinische Chemie und Pathobiochemie, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D Berlin, Germany. Fax ; frank.perschel@charite.de. Received February 23, 2004; accepted June 18, Previously published online at DOI: /clinchem (ng ml 1 h 1 ) and PAC/PRC ratios between 105 and 2328 pmol/mu. Whereas PAC or PRC showed broad overlap between PHA patients and volunteers, the PAC/ PRC ratio indicated distinct discrimination of these two groups at a cutoff of 71 pmol/mu. Conclusion: The PAC/PRC ratio offers several practical advantages compared with the PAC/PRA screening method. The present study offers preliminary evidence that it may be a useful screening test for PHA. Further studies are required to validate these results, especially in hypertensive cohorts American Association for Clinical Chemistry Primary hyperaldosteronism (PHA) 7 is recognized as the most common endocrine form of secondary hypertension [see, e.g., Refs. (1 6)] with an estimated prevalence between 5% and 15% in the hypertensive population (7). Because diagnosis of PHA facilitates effective therapy, extended screening including normokalemic patients is widely accepted (7 9). The most common screening test for PHA is the ratio of plasma aldosterone concentration to plasma renin activity (PAC/PRA) (7, 9). Because the measurement of PRA requires special preanalytical prerequisites, is timeconsuming, and shows poor interlaboratory reproducibility (10 12), this strategy is not well recommended for screening of hypertensive patients in primary care centers. The lower limit of detection varies among the different PRA assays; therefore, the effect on the PAC/PRA 7 Nonstandard abbreviations: PHA, primary hyperaldosteronism; PAC, plasma aldosterone concentration; PRA, plasma renin activity; PRC, plasma renin concentration; RLU, relative light unit(s); APA, aldosterone-producing adenoma; and IHA, idiopathic hyperaldosteronism. 1 Copyright 2004 by The American Association for Clinical Chemistry
2 2 Perschel et al.: Rapid Screening Test for PHA ratio and the resulting cutoff values for PHA can be dramatic (12). The validity and usefulness of the PAC/ PRA ratio for screening for PHA has therefore been challenged (13 15). Recently developed immunoassays for measurement of circulating renin in plasma (PRC) may overcome this limitation. However, studies evaluating these assays with regard to the diagnosis of PHA are rare (16, 17). An additional problem is that the proposed cutoff values published to date are derived from measurements of aldosterone in either plasma (2, 3, 6, 11, 13, 15, 17) or serum (1, 4, 16) and are based on different assays. Because both PRA and PRC are measured in plasma and because a simple screening test should be done from only a single specimen, aldosterone should also be measured in plasma. We therefore compared the new ratio between plasma aldosterone concentration and plasma renin concentration (PAC/PRC) with the established PAC/PRA screening test in patients with PHA and in healthy volunteers to evaluate its clinical and diagnostic significance. Materials and Methods immunoassays and instrumentation The PAC and PRC were measured on a fully automated chemiluminescence analyzer (Nichols Advantage ; Nichols Institute Diagnostics). This system incorporates sensitive acridinium ester detection technology in combination with magnetic particles as solid phase. Samples, reagents, and magnetic particles are pipetted into disposable cuvettes and incubated at 37 C until the reaction is stopped by a washing step, and the emitted light is measured in relative light units (RLU). The system is calibrated by a two-point recalibration against a stored master curve. PRC was measured with the Nichols Advantage Direct Renin TM assay. This two-site immunometric assay uses an acridinium-ester-labeled monoclonal antibody, a second biotinylated monoclonal antibody, and streptavidincoated magnetic particles. To avoid prorenin activation during the assay, the incubation time is limited to 30 min at 37 C. This assay is calibrated to the WHO reference material (National Institute for Biological Standards and Control code 68/356). In an evaluation study (18) this PRC assay showed the following performance: Precision. The intraassay variation for three samples with various concentrations of renin was %. Interassay variation in seven samples with renin concentrations from 10 to mu/l was between %. Accuracy. Dilution of four plasma samples with the sample diluent gave parallel lines whose slopes did not differ. Renin measurements in two series of mixtures prepared from two plasma samples with low and a high renin concentrations, respectively, yielded renin values between 86% and 111%. Limits of detection and functional sensitivity. The limits of detection, defined as the means plus 3 SD in two series of 20 runs of the sample diluent, were and mu/l, respectively. The functional sensitivity, defined as the sample renin concentration at which the CV for four series of five assay runs is 20%, was 2.65 mu/l; 1 mu/l is equivalent to 0.6 ng/l (18, 19). The aldosterone assay on Nichols Advantage is a competitive one-site immunometric assay, using a biotinylated monoclonal antibody bound to streptavidin-coated magnetic particles. Acridinium-ester-labeled aldosterone competes with sample aldosterone for the limited amount of biotinylated antibody. The cross-reactivity to any steroid hormones is negligible. According to the manufacturer s package insert, the assay has an analytical sensitivity of 33.3 pmol/l, and the dynamic range is pmol/l. The within-run imprecision (CV) at 119, 228, 547, 835, and 1990 pmol/l is 14.0%, 5.4%, 4.1%, 4.4%, and 2.9%, respectively. The total CV at 119, 228, 547, 835, and 1990 pmol/l is 18.6%, 8.5%, 5.2%, 6.3%, and 4.9%, respectively. Addition and dilution study results are between 88% and 110%. Parallelism results are between 92% and 102%. A method comparison with a commercially available RIA gave a correlation coefficient of 0.96 and a slope of 1.04; 1 pmol/l is equivalent to 0.36 ng/l. PRA was measured as described previously (10, 11). The intraassay variation of this assay was 3.9% at 11.7 ng ml 1 h 1 ; the interassay variation was 3.6% at 11.0 ng ml 1 h 1 and 6.2% at 3.29 ng ml 1 h 1, respectively. The detection limit was 0.40 ng ml 1 h 1. All laboratory testing was done by qualified staff of the Charité. The study was not performed as a blind study. Data analysis and estimation of cutoff values by use of ROC curve analysis were done with the Analyze-It software package (Analyze-It Software Ltd.). volunteers and patients We tested 76 healthy, normotensive volunteers [employees and students of the Charité; 23 males (age range, years) and 53 females (age range, years], who were not taking any relevant medications. Smoking and use of oral contraceptives were not exclusion criteria. Blood samples were drawn in an upright sitting posture. The patients studied included 28 patients with confirmed PHA [16 males and 12 females; mean (SD) age, 51 (13.1) years; age range, years]: 9 patients had aldosterone-producing adenomas (APAs), 18 had idiopathic hyperaldosteronism (IHA), and 1 patient had glucocorticoid-suppressible hyperaldosteronism. The characteristics of these PHA patients are summarized in Table 1. The screening of our patients was done according to a generally accepted protocol (7 9), in which plasma aldosterone was measured with a commercially available RIA (not with the new immunometric assay) and had to be 416 pmol/l (150 ng/l). The ratio between PAC and PRA had to be 555 (pmol/l)/(ng ml 1 h 1 )[ (200 ng/l)/(ng ml 1 h 1 )].
3 Clinical Chemistry 50, No. 9, Patient Sex Age, years Diagnosis Table 1. Characterization of 28 patients with confirmed PHA. a Confirmatory tests Differential diagnostic tests Saline infusion test b 24-h Urinary aldosterone c Posture Adrenal vein test d CT e or MRT f sampling g 1 F 46 APA left 2 ND Surgery 2 F 52 APA right ND 1 Lateral. Surgery 3 M 38 APA left 2 Lateral. Surgery 4 M 49 APA right 2 ND Surgery 5 F 50 APA right 2 ND Surgery 6 F 52 APA left ND 2 Lateral. Surgery 7 F 41 APA right ND 1 Lateral. Surgery 8 F 50 APA left 2 NU Surgery 9 M 38 APA left ND 2 ND Surgery 10 F 34 IHA 1 NU Spiro. 11 F 62 IHA ND NU No lateral. Spiro. 12 F 63 IHA 1 ND Spiro. 13 M 53 IHA ND 2 No Lateral. Spiro. 14 M 72 IHA 1 ND Amiloride 15 M 31 IHA ND NU No lateral. Spiro. 16 M 54 IHA 1 ND Eplerenone 17 F 31 IHA 1 ND Spiro. 18 M 59 IHA NU 1 ND Spiro. 19 M 60 IHA ND 1 No lateral. Amiloride 20 F 54 IHA ND 1 ND Spiro. 21 M 63 IHA 1 ND Spiro. 22 M 72 IHA 1 ND Others 23 M 52 IHA ND 1 ND Spiro. 24 M 68 IHA NU 1 ND Spiro. 25 M 59 IHA 1 No lateral. Spiro. 26 F 55 IHA ND 1 ND Spiro. 27 M 65 IHA ND 1 ND Amiloride 28 M 26 GSH h ND 2 ND Dexa., spiro. a For details on test protocols, see Quinkler et al. (8) and Young (12). Only specific medications, which were used after confirmatory and differential diagnostic tests, were given. Most patients with IHA needed additional antihypertensive drugs. b Saline infusion test:, plasma aldosterone 230 pmol/l ( 85 ng/l) after 2Lofisotonic saline; ND, not done. c 24-h Urinary aldosterone:, urinary aldosterone 39 nmol/day and urinary sodium 200 mmol/day; ND, not done; NU, not usable (urinary sodium 200 mmol/day). d Posture test: 2, decrease in plasma aldosterone; 1, increase in plasma aldosterone; NU, not useable because of concomitant increase in serum cortisol. e CT, computed tomography; MRT, magnetic resonance tomography; spiro., spironolactone; GSH, glucocorticoid-suppressible hyperaldosteronism; Dexa., dexamethasone. f CT or MRT:, unilateral tumor;, no tumor. g Adrenal vein sampling: lateral., lateralization; ND, not done; NU, not usable because of unsuccessful catheterization. h Glucocorticoid-suppressible hyperaldosteronism was confirmed by genetic testing. Therapy Diagnosis was confirmed by successful surgery (all APAs), pathologic saline infusion test (7 9), and increased 24-h urinary aldosterone excretion on a high sodium diet (12) (for details see Table 1). Seven of the 28 patients were normokalemic [mean (SD) serum potassium, 3.4 (0.5) nmol/l; range, mmol/l]. Systolic blood pressure was between 140 and 220 mmhg [mean (SD), 179 (21) mmhg], diastolic blood pressure was between 80 and 140 mmhg [mean (SD), 104 (12.5) mmhg]. The described characterization of the PHA patients was done routinely in the outpatient clinics of the departments of endocrinology at the Universities of Freiburg and Berlin. For this evaluation study, separate blood samples were drawn from all PHA patients in an upright sitting posture at The results presented in Tables 2 4 and Fig. 1 are from this standardized blood sampling. Although several authors have recommended PAC/PRA screening without discontinuing hypertensive medications (20 22), our study protocol for the evaluation of PAC/PRC was the following: Most of the patients were on antihypertensive therapy, but -blockers, angiotensin-converting enzyme inhibitors, angiotensin antagonists, and diuretics were stopped for at least 3 days and spironolactone for at least 4 weeks before blood sampling. Results evaluation of pac assay on nichols advantage The intraassay imprecision (CV) at concentrations of 114, 566, and 1906 pmol/l was 8.2%, 4.1%, and 4.4%, respec-
4 4 Perschel et al.: Rapid Screening Test for PHA Fig. 1. PAC, PRA, PRC, and the resulting PAC/PRA and PAC/PRC ratios for 76 healthy volunteers and 28 patients with PHA. The data points for PAC, PRA, PRC, and the ratios are plotted logarithmically;, healthy volunteers; F, patients with PHA. tively. The interassay CV at 128, 611, and 1956 pmol/l was 20%, 6.6% and 4.2%, respectively. The linearity on dilution was evaluated in two samples with concentrations of 525 and 1141 pmol/l. The measured concentrations were % of the expected. Parallelism in two samples of different concentrations was %. Calibration stability was evaluated with eight different calibrations. The CV was 3.0% for calibrator A (mean of RLU) and 3.2% for calibrator B (mean of RLU). The analytical sensitivity was 25 pmol/l. clinical results All methods tested (Fig. 1 and Table 2) differed significantly between PHA patients and healthy volunteers. Whereas single measurements of PAC, PRA or PRC concentrations showed broad overlap between both groups, the ratios PAC/PRA and PAC/PRC provided distinct discrimination between these two groups. PRC and PRA showed good correlation [Pearson regression coefficient (r) 0.72]. Because the same PAC values served for calculation of the ratios, PAC/PRC and PAC/PRA correlated similarly (r 0.73). As expected, differences occurred more frequently at the ends of lower renin concentration and activity ranges near the detection limits of both methods. ROC analysis (Table 3) showed the superiority of the ratios compared with PAC, PRA, and PRC alone. The PAC/PRC ratio performed as least as well as the PAC/ PRA ratio for differentiating PHA patients from healthy volunteers. With respect to the requirements of a screening test, we evaluated the cutoff values at a sensitivity of 100% (Tables 3 and 4). Discussion Because PHA is a common cause of secondary hypertension and its diagnosis can lead to cure or improvement of hypertension (APA) or targeted pharmacotherapy (IHA), validated and cost-effective routine screening protocols need to be established. At present, the most common screening test is the ratio Table 2. PAC, PRA, PRC, and the resulting PAC/PRA and PAC/PRC ratios for 76 healthy volunteers and 28 patients with PAH. Median (range) Method Units Healthy volunteers PHA patients PAC pmol/l 182 ( ) 751 ( ) PRA ng ml 1 h ( ) 0.57 ( ) PRC mu/l 27.8 ( ) 1.63 ( ) PAC/PRA (pmol/l)/ 46.9 ( ) 1393 ( ) (ng ml 1 h 1 ) PAC/PRC pmol/u 6.24 ( ) 388 ( ) PAC ng/l 65.8 ( ) 271 ( ) PRA ng ml 1 h ( ) 0.57 ( ) PRC ng/l 16.7 ( ) 0.98 ( ) PAC/PRA (ng/l)/ 16.9 ( ) 502 ( ) (ng ml 1 h 1 ) PAC/PRC ng/ng 3.75 ( ) 233 ( )
5 Clinical Chemistry 50, No. 9, Table 3. Calculated cutoff values and resulting specificity with respect to 100% sensitivity to differentiate patients with PHA from healthy volunteers. Method Units Optimum value for cutoff Sensitivity, % Specificity, % PAC pmol/l PRA ng ml 1 h PRC mu/l PAC/PRA (pmol/l)/ ratio (ng ml 1 h 1 ) PAC/PRC ratio pmol/mu between serum or plasma aldosterone (PAC) and PRA. Because several authors have determined PAC/PRA cutoffs to screen for PHA (1 9), this procedure is widely accepted as the best validated screening protocol. However, simultaneous measurement of PAC and PRA has some disadvantages: The method for measuring PRA requires cooling of the specimen during transport and storage, is time-consuming, and shows weak interlaboratory reproducibility (10 12). Because aldosterone is usually measured in serum, determination of the PAC/PRA ratio requires an additional, simultaneously drawn, blood tube. In addition, PAC, PRA, and the PAC/PRA ratio show large intra- and interpatient variations in patients with PHA (15); therefore, several authors have cast doubt on the validity and sensitivity of the PAC/PRA ratio (13 15). Alternative screening procedures that overcome these disadvantages seem to be necessary. Measurement of PRC instead of PRA may reduce some preanalytical and analytical problems and, therefore, improve intra- and interlaboratory reproducibility (23, 24). Major advantages of the new PAC and PRC assays evaluated in our study include the ease and performance of the test (no cooling, a single plasma sample, and good interlaboratory reproducibility because the assays are automated) and the rapid availability of results (automated immunochemiluminometric assays), which is a prerequisite for extensive screening of hypertensive patients for PHA. The performance of the new PAC assay was evaluated with a preliminary reagent lot. However, our results confirmed the assay specification given by the manufacturer. Because this is the first study with a fully automated system and only two studies with manual PRC assays for Table 4. Proposed cutoff values for the PAC/PRC ratio with different units used in the literature. Cutoff value PAC unit PRC unit for PAC/PRC pmol/l mu/l 71 pmol/l ng/l 118 ng/l mu/l 26 ng/l ng/l 43 screening for PHA have been published to date (16, 17), the comparison of our data with data from the literature is limited. Trenkel et al. (16) suggested a cutoff value of 50 (aldosterone measured in serum by RIA, expressed in ng/l; PRC measured by IRMA, expressed in ng/l), which corresponds to 83 when using the units in Table 2 (PAC expressed in pmol/l, PRC in mu/l). Ferrari et al. (17) recommended a cutoff of 150 (aldosterone measured in plasma by RIA, expressed in ng/l; PRC measured by IRMA, expressed in ng/l) corresponding to 90 when using the units in Table 2. Our data analysis (Tables 2 and 3; Fig. 1) produced a tentatively proposed cutoff value of 71. Subsequent studies including essential hypertensive cohorts may necessitate readjustment, although there is good concordance with the recommendations made by Trenkel et al. (16) and Ferrari et al. (17). Although the simultaneous measurement of PAC/PRC in plasma samples from 28 patients with known PHA showed no overlap with healthy volunteers (Fig. 1), there are certain limitations of our study: The PAC/PRC ratio seems to be superior to the PAC/PRA ratio. Although the PAC/PRA ratio of our PHA patients in the initial outpatient characterization was clearly above the cutoff value of 555 (pmol/l)/(ng ml 1 h 1 ) [200 (ng/l)/ (ng ml 1 h 1 )], the standardized reexamination of these patients by use of a second blood sample showed that some patients would have failed this diagnostic criterion. Our proposed cutoff value (Table 3), which was chosen to achieve a 100% sensitivity with the new automated assay, was therefore somewhat lower than the values recommended in the literature. In addition, some patients with confirmed PHA had PACs in the standardized reexamination that were 414 pmol/l (150 ng/l) and therefore would also fail the second diagnostic criterion for positive screening of PHA. Because there is no doubt in the correct characterization of our patients as having PHA, we have two explanations for these findings: (a) a recent study by Tanabe et al. (15) has demonstrated high intraindividual variability of PAC, PRA, and the PAC/PRA ratio in patients with PHA; and (b) because our plasma aldosterone was measured with the new immunochemiluminometric assay, these data show that each PAC and PRC assay requires separate validation of cutoff values. Evaluating diagnostic tests in a group of patients already known to have the disease and in a group of healthy volunteers can lead to overestimation of diagnostic accuracy (25). Thus, our data necessarily need to be complemented by further studies in hypertensive cohorts, e.g., in groups of patients with essential hypertension and groups with renovascular disease. The clinical conditions necessary for testing of the PAC/PRC or PAC/PRA ratios, such as discontinuing drug therapy, recording of dietary sodium intake, or time of day for sampling, are not yet sufficiently standardized, which contributes to the different published cutoff values and complicates the use of the screening test in clinical
6 6 Perschel et al.: Rapid Screening Test for PHA routine. An adequate standardization that meets general acceptance is required. In summary, our results suggest that the simultaneous measurement of PAC and PRC with automated immunochemiluminometric assays may be useful in the screening for PHA. Nevertheless, subsequent studies are required for further comparison of the PAC/PRC ratio vs the PAC/PRA ratio used for screening at present. These studies will have to deal with the following questions: (a) Because we tested only for the differentiation of patients from normotensive volunteers, has the PAC/PRC ratio similar sensitivities for screening of large hypertensive populations? Prospective studies are needed. (b) Is the newly developed assay for PAC really a method that offers reliable results if performed by different laboratories in clinical routine? (c) How is the PAC/PRC ratio influenced by clinical conditions, especially drug effects? Regardless of the answers to these questions, we expect that the new ratio method will evolve as a rapid and easily performed screening test for PHA. We would like to acknowledge J. Wilde for statistical calculations and P. Exner, R. Göber, K. Hanusa, and M. Schrödter for excellent technical assistance. References 1. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000;85: Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000;85: Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40: Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003;42: Lim PO, MacDonald TM. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clin Endocrinol (Oxf) 2003;59: Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after non-selective screening of hypertensive patients. J Hypertens 2003;21: Young WF Jr. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003;144: Quinkler M, Lepenies J, Diederich S. Primary hyperaldosteronism. Exp Clin Endocrinol Diabetes 2002;110: Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002;31: Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992;75: Oelkers W, Diederich S, Bahr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. J Clin Endocrinol Metab 2000;85: Young WF Jr. Primary aldosteronism: management issues. Ann N Y Acad Sci 2002;970: Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001;76: Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002;48: Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003;88: Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002;110: Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004;22: De Bruin RA, Bouihuizen A, Diederich S, Perschel FH, Boomsma F, Deinum J. Validation of a new rapid renin assay. Clin Chem; in press. 19. Simon D, Hartmann DJ, Badouaille G, Caillot G, Guyenne TT, Corvol P, et al. Two-site direct immunoassay specific for active renin. Clin Chem 1992;38: Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002;57: Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40: Cartledge S, Lawson N. Aldosterone and renin measurements. Ann Clin Biochem 2000;37: Morganti A, Pelizzola D, Mantero F, Gazzano G, Opocher G, Piffanelli A, on behalf of the Italian Multicenter Study for Standardization of Renin Measurement. Immunoradiometric versus enzymatic renin assay: results of the Italian Multicenter Comparative Study. J Hypertens 1995;13: Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JHP, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:
Clarification of hypertension Diagnosis of primary hyperaldosteronism
Nr. 1/2010 Clarification of hypertension Diagnosis of primary hyperaldosteronism Marc Beineke The significance of the /renin ratio (ARR) in the diagnosis of normoalaemic and hypokalaemic primary hyperaldosteronism,
More informationComparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass
European Journal of Endocrinology (2004) 150 517 523 ISSN 0804-4643 CLINICAL STUDY Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in
More informationRecent studies have demonstrated that primary aldosteronism
Primary Aldosteronism and Hypertensive Disease Lorena Mosso, Cristian Carvajal, Alexis González, Adolfo Barraza, Fernando Avila, Joaquín Montero, Alvaro Huete, Alessandra Gederlini, Carlos E. Fardella
More informationAutomated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without Extraction Steps
Clinical Chemistry 52:9 1749 1755 (2006) Automation and Analytical Techniques Automated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without
More informationYear 2004 Paper two: Questions supplied by Megan 1
Year 2004 Paper two: Questions supplied by Megan 1 QUESTION 96 A 32yo woman if found to have high blood pressure (180/105mmHg) at an insurance medical examination. She is asymptomatic. Clinical examination
More informationPrimary Aldosteronism: screening, diagnosis and therapy
Primary Aldosteronism: screening, diagnosis and therapy Jacques W.M. Lenders, internist DEPT. OF INTERNAL MEDICINE, RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTER, NIJMEGEN,THE NETHERLANDS DEPT. OF INTERNAL
More informationUpon completion, participants should be able to:
Learning Objectives Upon completion, participants should be able to: Describe the causes of secondary hypertension and the prevalence of primary aldosteronism Discuss the diagnostic approach to primary
More informationPrimary aldosteronism clinical practice guidelines: a re-appraisal The Management of Primary Aldosteronism
Primary aldosteronism clinical practice guidelines: a re-appraisal The Management of Primary Aldosteronism Prof. FRANCO MANTERO Division of Endocrinology University of Padua Italy Case Detection, Diagnosis
More informationConfirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites
European Journal of Endocrinology (6) 154 865 873 ISSN 84-4643 CLINICAL STUDY Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone
More informationRoles of Clinical Criteria, Computed Tomography Scan, and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes
ORIGINAL Endocrine ARTICLE Care Roles of Clinical Criteria, Computed Tomography Scan, and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes Paolo Mulatero, Chiara Bertello,
More informationPrimary Aldosteronism in Diabetic Subjects with Resistant Hypertension
Diabetes Care In Press, published online April 11, 2007 Primary Aldosteronism in Diabetic Subjects with Resistant Hypertension Received for publication 8 January 2007 and accepted in revised form 30 March
More informationPrimary Aldosteronism
Primary Aldosteronism Odelia Cooper, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes, and Metabolism Cedars-Sinai Medical Center HYPERTENSION CENTER Barriers to diagnosing primary
More informationUpdates in primary hyperaldosteronism and the rule
Updates in primary hyperaldosteronism and the 20-50 rule I. David Weiner, M.D. Professor of Medicine and Physiology and Functional Genomics University of Florida College of Medicine and NF/SGVHS The 20-50
More informationAldosterone on Liaison XL In use date: June 6, 2017
Aldosterone on Liaison XL In use date: June 6, 2017 I. PRINCIPLE Aldosterone is a steroid hormone of molecular weight 360.4 daltons, the major mineralcorticoid secreted by the adrenal cortex. The role
More informationAbout 20% of the Canadian population
Mineralocorticoid Hypertension: Common and Treatable Hypertension is the most common chronic disease treated by the primary-care physician. It is now evident that mineralocorticoid hypertension, which
More informationGuideline PA. Renin. Renin From a Laboratory Perspective. Use of renin and aldosteron measurements. UMCG Dept. Laboratory Medicine
UMCG Dept. Laboratory Medicine SKML symposium Endocriene hypertensie Renin From a Laboratory Perspective Anneke Muller Kobold Clinical Chemist Endocrinology Laboratory of Binding Analysis University Medical
More informationThe Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
SPECIAL FEATURE Clinical Practice Guideline The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline John W. Funder, Robert M.
More informationPrevalence of Primary Hyperaldosteronism in a Systemic Arterial Hypertension League
Prevalence of Primary Hyperaldosteronism in a Systemic Arterial Hypertension League Maria Jacqueline Silva Ribeiro, José Albuquerque de Figueiredo Neto, Edson Viriato Memória, Maíra de Castro Lopes, Manuel
More informationThe Clinical Value of Salivary Aldosterone in Diagnosis and Follow-Up of Primary Aldosteronism
638 Endocrine Care The Clinical Value of Salivary Aldosterone in Diagnosis and Follow-Up of Primary Aldosteronism Authors U. D. Lichtenauer 1, 2, S. Gerum 1, 3, E. Asbach 1, J. Manolopoulou 1, 4, V. Fourkiotis
More informationScreening for primary aldosteronism in an argentinian population: a multicenter prospective study
original article Screening for primary aldosteronism in an argentinian population: a multicenter prospective study Mariela Leal Reyna 1, Reynaldo M. Gómez 2, Susana N. Lupi 3, Susana H. Belli 4, Cecilia
More informationSpectrum of Hypertension & Hypokalemia
Spectrum of Hypertension & Hypokalemia Farheen K. Dojki, PGY-6 Hypertension Fellow, ASH Hypertension Center Dr. Dojki does not have any relevant financial relationships with any commercial interests. OBJECTIVES:
More informationImprove the Hypertension Management
Improve the Hypertension Management Ask for LIAISON Aldosterone and Direct Renin Assays FOR OUTSIDE THE US ONLY Improve the Hypertension Management DiaSorin The Solution Hypertension worldwide estimation
More informationResistant hypertension, defined as a failure of concomitant. Efficacy of Low-Dose Spironolactone in Subjects With Resistant Hypertension
AJH 2003; 16:925 930 Efficacy of Low-Dose Spironolactone in Subjects With Resistant Hypertension Mari Konishi Nishizaka, Mohammad Amin Zaman, and David A. Calhoun Background: Previous reports have demonstrated
More informationUpdates in primary hyperaldosteronism and the rule
Updates in primary hyperaldosteronism and the 20-50 rule I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of
More informationAldosterone-to-renin ratio as a screening test for primary aldosteronism The Dutch
SPECIAL REPORT Aldosterone-to-renin ratio as a screening test for primary aldosteronism The Dutch ARRAT Study P.M. Jansen *, F. Boomsma, A.H. van den Meiracker, the Dutch ARRAT investigators Department
More informationProspective Study on the Prevalence of Secondary Hypertension among Hypertensive Patients Visiting a General Outpatient Clinic in Japan
193 Original Article Prospective Study on the Prevalence of Secondary Hypertension among Hypertensive Patients Visiting a General Outpatient Clinic in Japan Masao OMURA, Jun SAITO, Kunio YAMAGUCHI, Yukio
More informationA 64 year old man referred for evaluation of suspected hyperaldosteronism
A 64 year old man referred for evaluation of suspected hyperaldosteronism Dr. Dickens does not have any relevant financial relationships with any commercial interests. ENDORAMA: 64 year old man referred
More informationPrimary aldosteronism (PA) is a common form of endocrine
Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism Paolo Mulatero, Franco Rabbia, Alberto Milan, Cristina Paglieri, Fulvio Morello, Livio Chiandussi, Franco Veglio Abstract
More informationAdrenal Vein Sampling: A Critical Tool for Subtyping Primary Aldosteronism
Adrenal Vein Sampling: A Critical Tool for Subtyping Primary Aldosteronism Disclosures No conflicts of interest relevant to this presentation Jason W. Pinchot, M.D. Assistant Professor, Vascular and Interventional
More informationHow to Recognize Adrenal Disease
How to Recognize Adrenal Disease CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi
More informationACTH stimulation test and computed tomography are useful for differentiating the subtype of primary aldosteronism
2017, 64 (1), 65-73 Original ACTH stimulation test and computed tomography are useful for differentiating the subtype of primary aldosteronism Ayako Moriya 1), Masaaki Yamamoto 1), Shunsuke Kobayashi 1),
More informationOriginal Article. Roberto FOGARI 1), Paola PRETI 1), Annalisa ZOPPI 1), Andrea RINALDI 1), Elena FOGARI 1), and Amedeo MUGELLINI 1) Introduction
111 Original Article Hypertens Res Vol.30 (2007) No.2 p.111-117 Prevalence of Primary Aldosteronism among Unselected Hypertensive Patients: A Prospective Study Based on the Use of an Aldosterone/Renin
More informationOutpatient Fludrocortisone Suppression Test: A Safe and Effective Alternative to Inpatient
Outpatient Fludrocortisone Suppression Test: A Safe and Effective Alternative to Inpatient Testing/ Original Article Author Information Dr Walter van der Merwe MBChB, FRACP, Consultant Nephrologist, Renal
More informationDiagnostic Role of Captopril Challenge Test in Korean Subjects with High Aldosterone-to-Renin Ratios
Original Article Endocrinol Metab 2016;31:277-283 http://dx.doi.org/10.3803/enm.2016.31.2.277 pissn 2093-596X eissn 2093-5978 Diagnostic Role of Captopril Challenge Test in Korean Subjects with High Aldosterone-to-Renin
More informationDiagnostic Accuracy of Adrenal Venous Sampling in Comparison with Other Parameters in Primary Aldosteronism
Endocrine Journal 2008, 55 (5), 839 846 Diagnostic Accuracy of Adrenal Venous Sampling in Comparison with Other Parameters in Primary Aldosteronism ISAO MINAMI, TAKANOBU YOSHIMOTO, YUKI HIRONO, HAJIME
More informationIN RECENT YEARS, growing evidence has consistently
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(9):4221 4226 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-032179 Aldosterone to Renin Ratio
More informationADRENAL VEIN SAMPLING: AN INTEGRAL PART OF MANAGING COMPLICATED ADRENAL HYPERTENSION- SAFE? WORTH IT?
ADRENAL VEIN SAMPLING: AN INTEGRAL PART OF MANAGING COMPLICATED ADRENAL HYPERTENSION- SAFE? WORTH IT? Chaitanya Ahuja, M.D. Assistant Professor, Vascular and Interventional Radiology Director of Interventional
More informationPrimary Aldosteronism & Implications for Primary Hypertension
& Implications for Primary Hypertension Richard J. Auchus, MD, PhD, FACE Professor and Fellowship Program Director Depts of Internal Medicine/MEND & Pharmacology University of Michigan Disclosures Contracted
More informationAVS and IPSS: The Basics and the Pearls
AVS and IPSS: The Basics and the Pearls William F. Young, Jr., MD, MSc Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA 2018 Mayo Foundation for Medical Education and Research.
More informationPrimary aldosteronism (PA) is currently believed to be
Aldosterone Impact of Different Diagnostic Criteria During Adrenal Vein Sampling on Reproducibility of Subtype Diagnosis in Patients With Primary Aldosteronism Paolo Mulatero, Chiara Bertello, Norlela
More informationReferences Required document for Laboratory Accreditation by the College of American Pathologists.
Subject NT-proBNP Cobas e601 Index Number Lab-4011 Section Laboratory Subsection Chemistry Category Departmental Contact Benjamin Michel Last Revised 10/19/2016 References Required document for Laboratory
More informationMeasurement of Renin Activity using Tandem Mass Spectrometry Ravinder J Singh, PhD, DABCC Mayo Clinic, Rochester, MN
Measurement of Renin Activity using Tandem Mass Spectrometry Ravinder J Singh, PhD, DABCC Mayo Clinic, Rochester, MN Renin Angiotension System Weber, et al. NEJM 2001; 345:1690. Renin Angiotension System
More informationPrevalence of Hyperaldosteronism in Primary Care Patients with Resistant Hypertension
ORIGINAL RESEARCH Prevalence of Hyperaldosteronism in Primary Care Patients with Resistant Hypertension Guido Schmiemann, MD, MPH, Klaus Gebhardt, MD, Eva Hummers-Pradier, MD and Günther Egidi, MD Introduction:
More informationA case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY
A case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY Case 57 y.o. male CC: Weakness HPI: About 20 years ago, he developed bilateral lower extremity weakness. Laboratory
More informationBimodal Aldosterone Distribution in Low-Renin Hypertension
American Journal of Hypertension Advance Access published June 11, 2013 Original article Bimodal Aldosterone Distribution in Low-Renin Hypertension E. Victor Adlin, 1 Leonard E. Braitman, 2 and Ramachandran
More information25-Hydroxy Vitamin D TOTAL (25HD) on Liaison XL
25-Hydroxy Vitamin D TOTAL (25HD) on Liaison XL I. PRINCIPLE The role of vitamin D in bone and mineral metabolism was recognized from its first identification as a factor that could cure rickets. However,
More informationEvaluation of Endocrine Tests B: screening for hypercortisolism
O R I G I N A L A R T I C L E Evaluation of Endocrine Tests B: screening for hypercortisolism F. Holleman 1*, E. Endert 2, M.F. Prummel 1, M. van Vessem-Timmermans 1, W.M. Wiersinga 1, E. Fliers 1 1 Department
More information25(OH) Vitamin D ELISA (BD-220BA), 192 Tests
INTENDED USE The 25-hydroxy (25-OH) Vitamin D ELISA is intended for the quantitative determination of total 25-OH Vitamin D in human serum and Plasma. SUMMARY AND EXPLANATION Vitamin D is a steroid hormone
More informationEndocrine hypertensionmolecules. Marie Freel Caledonian Endocrine Society Meeting 29 th November 2015
Endocrine hypertensionmolecules and genes Marie Freel Caledonian Endocrine Society Meeting 29 th November 2015 Plan Mineralocorticoid hypertension Myths surrounding Primary Aldosteronism (PA) New developments
More informationSee external label 2 C-8 C Σ=96 tests Cat # 6101Z. Cortisol. Cat # 6101Z
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationPrevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing
ORIGINAL PAPERS Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing Sue Hood, John Cannon, Roger Foo and Morris Brown ABSTRACT Recent studies have suggested
More informationMultiple studies are available concerning the use of
SPECIAL ARTICLE Evaluation of the Biosite Ò Quantitative Whole Blood D-dimer Assay and Comparison With the biomérieux VIDAS Ò D-dimer Exclusion Test Validation and Utility For Use in the Central Laboratory
More informationRaised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study
Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study P. O. Lim, R. T. Jung & T. M. MacDonald Hypertension Research Centre, Department
More informationQMS TACROLIMUS APPLICATION BECKMAN COULTER AU480 /AU680 /AU5800
QMS TACROLIMUS APPLICATION BECKMAN COULTER AU480 /AU680 /AU5800 Beckman Coulter Reagent REF A53727 The QMS Tacrolimus Immunoassay is intended for the quantitative determination of tacrolimus in human whole
More informationMineralocorticoids: aldosterone Angiotensin II/renin regulation by sympathetic tone; High potassium will stimulate and ACTH Increase in aldosterone
Disease of the Adrenals 1 Zona Glomerulosa Mineralocorticoids: aldosterone Angiotensin II/renin regulation by sympathetic tone; High potassium will stimulate and ACTH Increase in aldosterone leads to salt
More informationInterrelationship between Angiotensin Catecholamines. Tatsuo SATO, M.D., Masaru MAEBASHI, M.D., Koji GOTO, M.D., and Kaoru YOSHINAGA, M.D.
Interrelationship between Angiotensin and Catecholamines Tatsuo SATO, M.D., Masaru MAEBASHI, M.D., Koji GOTO, M.D., and Kaoru YOSHINAGA, M.D. SUMMARY Urinary catecholamines were measured with an attempt
More informationENDOCRINE FORMS OF HYPERTENSION. Michael Stowasser
ENDOCRINE FORMS OF HYPERTENSION Michael Stowasser Hypertension Unit, University Department of Medicine, Princess Alexandra Hospital, Brisbane 4102, Australia. ENDOCRINE FORMS OF HYPERTENSION Mineralocorticoid
More informationThe endocrine system is made up of a complex group of glands that secrete hormones.
1 10. Endocrinology I MEDCHEM 535 Diagnostic Medicinal Chemistry Endocrinology The endocrine system is made up of a complex group of glands that secrete hormones. These hormones control reproduction, metabolism,
More informationAVS and IPSS: The Basics and the Pearls William F. Young, Jr., MD, MSc Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA
AVS and IPSS: The Basics and the Pearls William F. Young, Jr., MD, MSc Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA 2016 Mayo Foundation for Medical Education and Research.
More information(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)
cobas b system - performance evaluation Study report from a multicenter evaluation of the new cobas b system for the measurement of HbAc and lipid panel Introduction The new cobas b system provides a point-of-care
More informationDiagnosis of primary aldosteronism (PA), the most frequent
Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism Silvia Monticone, Fumitoshi Satoh, Gilberta Giacchetti, Andrea Viola, Ryo Morimoto, Masataka Kudo,
More informationMasaaki Inaba, 1* Kiyoshi Nakatsuka, 1 Yasuo Imanishi, 1 Masakazu Watanabe, 2 Yuji Mamiya, 2 Eiji Ishimura, 1 and Yoshiki Nishizawa 1.
Clinical Chemistry 50:2 385 390 (2004) Endocrinology and Metabolism Technical and Clinical Characterization of the Bio-PTH (1 84) Immunochemiluminometric Assay and Comparison with a Second-Generation Assay
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fenske W, Refardt J, Chifu I, et al. A copeptin-based approach
More informationCortisol (Sheep) ELISA Kit
Cortisol (Sheep) ELISA Kit Catalog Number KA0919 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the
More informationPrimary and secondary hyperaldosteronism. Zsolt Turóczi, M.D. 2nd Department of Internal Medicine
Primary and secondary hyperaldosteronism Zsolt Turóczi, M.D. 2nd Department of Internal Medicine Adrenal gland Adrenal cortex Carey RM. Primary aldosteronism. Journal of Surgical Oncology 2012: 106; 575
More informationUSING THE ACCESS AMH ASSAY IN YOUR LABORATORY
INFORMATION BULLETIN USING THE ACCESS AMH ASSAY IN YOUR LABORATORY ///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
More informationSee external label 2 C-8 C Σ=96 tests Cat # 3171Z. Free Estriol. Cat # 3171Z. Enzyme Linked Immunosorbent Assay
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationGuidelines for the diagnosis and treatment of primary aldosteronism -The Japan Endocrine Society 2009-
Endocrine Journal 2011, 58 (9), 711-721 Guidelines for the diagnosis and treatment of primary aldosteronism -The Japan Endocrine Society 2009- Tetsuo Nishikawa 1), Masao Omura 2), Fumitoshi Satoh 3), Hirotaka
More informationLIAISON ACTH (REF )
For Professional Use Only! DiaSorin S.p.A. Strada per Crescentino-13040 Saluggia (Vercelli)-Italy Tel. +39.0161.487.093 Fax +39.0161.487.628 LIAISON ACTH (REF 313221) 1. INTENDED USE The LIAISON ACTH assay
More informationA clinical prediction score for diagnosing unilateral primary Aldosteronism may not be generalizable
Venos et al. BMC Endocrine Disorders 2014, 14:94 RESEARCH ARTICLE Open Access A clinical prediction score for diagnosing unilateral primary Aldosteronism may not be generalizable Erik S Venos 1, Benny
More information--Manuscript Draft-- Primary Aldosteronism; adrenal vein sampling; aldosterone producing adenoma. Brisbane, Queensland, AUSTRALIA
Journal of Hypertension Repeating adrenal vein sampling when neither aldosterone/cortisol ratio exceeds peripheral yields a high incidence of aldosterone-producing adenoma --Manuscript Draft-- Manuscript
More informationBÜHLMANN fcal turbo. Calprotectin turbidimetric assay for professional use. Reagent Kit B-KCAL-RSET. Revision date:
BÜHLMANN fcal turbo Calprotectin turbidimetric assay for professional use Reagent Kit B-KCAL-RSET Revision date: 2017-02-24 BÜHLMANN LABORATORIES AG Baselstrasse 55 4124 Schönenbuch, Switzerland Tel.:
More informationEndocrine. Endocrine as it relates to the kidney. Sarah Elfering, MD University of Minnesota
Endocrine Sarah Elfering, MD University of Minnesota Endocrine as it relates to the kidney Parathyroid gland Vitamin D Endocrine causes of HTN Adrenal adenoma PTH Bone Kidney Intestine 1, 25 OH Vitamin
More informationInstructions for use. TSH rat ELISA. Please use only the valid version of the Instructions for Use provided with the kit AR E-8600
Instructions for use TSH rat ELISA AR E8600 TSH rat ELISA INTRODUCTION INTENDED USE The TSH rat ELISA is an enzyme immunoassay for the quantitative measurement of TSH in rat serum. For research use only.
More informationAldosterone and Cardiovascular Disease
Aldosterone and Cardiovascular Disease Krishna K. Gaddam, MD, Eduardo Pimenta, MD, Saima Husain, MD, and David A. Calhoun, MD Abstract: Aldosterone is an adrenal hormone that regulates sodium, fluid, and
More informationResistant hypertension is defined as blood. Primary Hyperaldosteronism Decoded: A Case of Curable Resistant Hypertension.
Case Review Primary Hyperaldosteronism Decoded: A Case of Curable Resistant Hypertension Timothy R. Larsen, DO, Wadie David, Susan Steigerwalt, MD, Shukri David, MD Department of Internal Medicine, Section
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationA German family with glucocorticoid-remediable aldosteronism
Nephrol Dial Transplant (2007) 22: 1123 1130 doi:10.1093/ndt/gfl706 Advance Access publication 3 February 2007 Original Article A German family with glucocorticoid-remediable aldosteronism Oliver Vonend
More informationGentian Canine CRP Immunoassay Application Note for scil VitroVet*
v02-jan2014 Gentian Canine CRP Immunoassay Application Note for scil VitroVet* Intended Use The canine CRP immunoassay on scil VitroVet is an in vitro diagnostic test for quantitative determination of
More informationPatterns of Sodium Excretion During Sympathetic Nervous System Arousal. Gregory A. Harshfield, Derrick A. Pulliam, and Bruce S.
1156 Patterns of Sodium Excretion During Sympathetic Nervous System Arousal Gregory A. Harshfield, Derrick A. Pulliam, and Bruce S. Alpert The purpose of this study was to examine Na + handling and regulation
More informationA Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients
Journal of the American College of Cardiology Vol. 48, No. 11, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.07.059
More informationReview Article Changes in the Perceived Epidemiology of Primary Hyperaldosteronism
SAGE-Hindawi Access to Research International Hypertension Volume 2011, Article ID 162804, 7 pages doi:10.4061/2011/162804 Review Article Changes in the Perceived Epidemiology of Primary Hyperaldosteronism
More informationThe Adiponectin Turbidimetric Immunoassay Reagent Kit
The Adiponectin Turbidimetric Immunoassay Reagent Kit Catalogue number: 51010 For the quantitative determination of Adiponectin in human serum and plasma This package insert must be read in its entirety
More informationTotal Thyroxine ELISA (T4)
Design Verification Total Thyroxine ELISA (T4) Contents 1 Assay Principle... 2 2 Imprecision... 2 Within-run Imprecision... 2 Between run Imprecision... 2 3 Comparison of Methods, Accuracy... 2 4 Linearity...
More informationDBC s panel of thyroid hormone immunoassays is now more comprehensive with the new Reverse T3 ELISA kit. Test Your Hormones
DBC s panel of thyroid hormone immunoassays is now more comprehensive with the new Reverse T3 ELISA kit Test Your Hormones INTRODUCTION For years thyroid hormone testing has been concentrated on TSH and
More informationBNP Fragment EIA (Cat.No. BI-20852W) For the Determination of BNP Fragment in Human Samples
BNP Fragment EIA (Cat.No. BI-20852W) For the Determination of BNP Fragment in Human Samples ASSAY CHARACTERISTICS Method Competitive Enzyme Immunoassay, HRP/TMB. Microtiter plates are coated with a polyclonal
More informationAdrenocorticotropic Hormone (ACTH) ELISA
For Research Use Only. Not for use in Diagnostic Procedures. INTENDED USE The GenWay, Inc. ACTH ELISA Kit is intended for the quantitative determination of ACTH Adrenocorticotropic Hormone) in human plasma
More informationCase report. Open Access. Abstract
Open Access Case report Hypokalemia induced myopathy as first manifestation of primary hyperaldosteronism an elderly patient with unilateral adrenal hyperplasia: a case report Panagiotis Kotsaftis 1, Christos
More informationIV2-113E Use by. Invitron Glargine ELISA Kit REF LOT IVD. Definitions. English. For in-vitro diagnostic use. Instructions for use.
Definitions Instructions for use REF Catalogue number IV2-113E Use by English Invitron Glargine ELISA Kit For in-vitro diagnostic use Σ 96 LOT IVD Lot/Batch Code Storage temperature limitations In vitro
More informationPREOPERATIVE DIAGNOSIS AND LOCALIZATION OF ALDOSTERONE-PRODUCING ADENOMA BY ADRENAL VENOUS SAMPLING AFTER ADMINISTRATION OF METOCLOPRAMIDE
K.D. Wu, T.S. Liao, Y.M. Chen, et al PREOPERATIVE DIAGNOSIS AND LOCALIZATION OF ALDOSTERONE-PRODUCING ADENOMA BY ADRENAL VENOUS SAMPLING AFTER ADMINISTRATION OF METOCLOPRAMIDE Kwan-Dun Wu, Tsou-Song Liao,
More informationFour rules to remember: 1) Addition, subtraction, multiplication and division of SD and/or CV.
Analytical Quality Specifications for Thyroid Hormones Bayer Nordic Users Meeting, 17. September 2001. Frode Engbaek, Ph. D., Department of Clinical Biochemistry, Aarhus Kommunehospital, DK-8000 Aarhus
More informationPrevalence and characterization of somatic mutations in Chinese aldosterone-producing adenoma. patients. Supplemental data. First author: Baojun Wang
Prevalence and characterization of somatic mutations in Chinese aldosterone-producing adenoma patients Supplemental data First author: Baojun Wang Patients and tumor samples A total of 87 patients with
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationChanges in the clinical manifestations of primary aldosteronism
ORIGINAL ARTICLE Korean J Intern Med 2014;29:217-225 Changes in the clinical manifestations of primary aldosteronism Sun Hwa Kim, Jae Hee Ahn, Ho Cheol Hong, Hae Yoon Choi, Yoon Jung Kim, Nam Hoon Kim,
More informationAldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism
Schilbach Katharina et al. Aldosterone to Renin Ratio Exp Clin Endocrinol Diabetes 2018; 00: 00 00 Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism Authors Katharina Schilbach 1, *,
More informationStandard Operating Procedure
Subject Free Thyroxine (FT4-II) cobas e411 Index Number Lab-1594 Section Regional/Affiliate Subsection Laboratory Category Departmental Contact Goplin, Darcy Last Revised 2/2/2017 References Required document
More informationDiagnostic reagent for quantitative in vitro determination of Urea / Blood Urea Nitrogen in serum, plasma and urine by colorimetry.
2013/07/30 A93A01315AUS A11A01641 60 ml 15 ml Pentra C400 Diagnostic reagent for quantitative in vitro determination of Urea / Blood Urea Nitrogen in serum, plasma and urine by colorimetry. QUAL-QA-TEMP-0846
More informationTSH ELISA Kit Medical Device Licence No.: 16419
TSH ELISA Kit Medical Device Licence No.: 16419 Enzyme immunoassay kit for the quantitative determination of TSH concentration in serum. Catalog Number: SL100305 Catalog Number: SL100306 Catalog Number:
More informationMLT Intact Proinsulin Kit
IV2-002 English MLT Intact Proinsulin Kit For in-vitro diagnostic use only MLT (Molecular Light Technology) Chemiluminescence assay for the measurement of Intact Proinsulin in human samples. 480 Invitron
More informationThyroid Stimulating Hormone (TSH) ELISA Catalog No. GWB , legacy id (96 Tests)
For Research Use Only. Not for use in Diagnostic Procedures. INTENDED USE The GenWay, Inc. TSH ELISA Kit is intended for the quantitative measurement of TSH in human serum or plasma. For research use only.
More information